Amgen Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.Amgen Inc. (AMGN) shares rose 1.22% to $376.04 on Friday, marking its second consecutive day of gains amid a favorable market session where the S&P 500 and Dow Jones also increased. However, Amgen underperformed relative to some competitors; Johnson & Johnson and AbbVie saw larger percentage gains, while Pfizer declined slightly. The stock closed 3.90% below its 52-week high of $391.29. Trading volume was lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Amgen Inc. (AMGN) rose 1.22% to $376.04 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.05% to 7,411.98 and the Dow Jones Industrial Average rising 0.46% to 51,947.25.
This was the stock's second consecutive day of gains.
Amgen Inc. closed 3.90% below its 52-week high of $391.29, which the company reached on March 2nd.
The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 1.59% to $263.40, Pfizer Inc. (PFE) fell 0.16% to $24.54, and AbbVie Inc. (ABBV) rose 0.95% to $259.36.
Trading volume (2.4 M) remained 237,584 below its 50-day average volume of 2.7 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 24, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-24-26 1635ET